Dr. Klaus Schmierer completed his training at the Charité Hospital (Humboldt University Berlin) before moving to London to pursue a career in academic neurology. Initially working as a research fellow, from 2005 he was a Wellcome Intermediate Clinical Fellow at the University College London Institute of Neurology and then Consultant Neurologist at The National Hospital, Queen Square, London, UK. Following appointments in 2009 at Queen Mary and Barts Health, he moved to his current position in East London.

Multiple Scelrosis (MS) has been a focus of Dr. Schmierer’s clinical and research activities from the beginning of his training in Neurology at the Charité Hospital (Humboldt University Berlin). His clinical academic work now includes exploring the pathological substrate of disease deterioration in people living with MS (PwMS) using magnetic resonance imaging (MRI) and quantitative histology and studies into the epidemiology and cause(s) of MS and has helped develop the BartsMS Database; in vivo MRI studies to improve the differential-diagnosis of MS; and investigator-led and commercial clinical trials.

From 2013–2015, Dr. Schmierer served as a member of the Association of British Neurologists’ MS & Neuroinflammation Specialist Subcommittee which published the latest UK disease-modifying treatment guidelines for PwMS. He has been the Deputy Director of the Research & Development Board in the Emergency Care & Acute Medicine Clinical Academic Group of Barts Health National Health Service Trust. He is the Past-Chair of the White Matter Study Group of the International Society for Magnetic Resonance in Medicine, and serves on the MS Society’s Clinical Trials Network, their consortium for progressive MS, as well as the review board of the MS Register. Dr. Schmierer is the sub-speciality lead for MS at the National Institute for Health and Care Research North Thames Clinical Research Network, and acts as an advisor to the European Medicines Agency, Medicines and Healthcare Products Regulatory Agency, and National Institute for Health and Care Excellence on new drugs for MS.